Michael Zolman
Optometrist · Charleston, SCNPI 1902942444
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Lumenis BE Inc accounts for 60.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $6,230 and has fallen 70.5% since, to $1,840 in 2025. Among optometrist clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $117.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$8K
- Alcon$2K
- Coopervision Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$451
- Johnson & Johnson Vision Care, Inc.$315
- Mallinckrodt Hospital Products Inc.$303
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$2422%
- Food & beverage$12,95595%
- Education$1981%
- Entertainment$2702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 3 | $8,269 |
| Alcon | 45 | $1,920 |
| Coopervision Inc. | 24 | $1,401 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $451 |
| Johnson & Johnson Vision Care, Inc. | 10 | $315 |
| Mallinckrodt Hospital Products Inc. | 4 | $303 |
| Optos, Inc. | 3 | $270 |
| Alcon Research LLC | 5 | $127 |
| Shire North American Group Inc | 1 | $124 |
| Biotissue Holdings Inc. | 1 | $122 |
| Novartis | 4 | $90 |
| Carl Zeiss Meditec USA, Inc. | 2 | $62 |
| Maculogix, Inc. | 1 | $52 |
| LKC Technologies, Inc. | 2 | $41 |
| Bausch & Lomb Americas Inc. | 2 | $37 |
| AbbVie(2 entities) | 2 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $27 |
| Oyster Point Pharma, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$6,669
- M22$1,600
- MyDay Contact Lens$344
- TOTAL30$321
- DAILIES$290
- ULTRA$247
- PANORAMIC OPHTHALMOSCOPE$241
- OCT OPHTHALMOSCOPE$241
- Precision 1$220
- Clariti Contact Lens$126
- XIIDRA$124
- Prokera$122
- AmnioGraft$122
- NFC-700$120
- MiSight Contact Lens$117
- BIOTRUE ONE DAY$115
- P200DTx$100
- P200T$100
- P200TE$100
- P200TxE$100
How this compares
$13,665 in reported general payments places this provider in the 95th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $14,201 |
| LumiganBimatoprost | 22 | $10,237 |
| MieboPerfluorohexyloctane/Pf | 11 | $8,110 |
| Cyclosporine | 14 | $6,822 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $5,535 |
| Travoprost | 13 | $1,639 |
| Brimonidine Tartrate | 24 | $426 |
| Latanoprost | 47 | $411 |
| Timolol Maleate | 41 | $398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $31 | $29,97368 claims |
| Bausch & Lomb Americas Inc.Miebo | $37 | $8,11011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Charleston
- Richard BedellCharleston$55K
- Jennifer ZolmanCharleston$21K
- Chad CarlssonCharleston$13K
- Michele DonovanCharleston$7K
- William DentonCharleston$7K
- Elyse DewittCharleston$6K
- Jensen RafoolCharleston$6K
- Alexa RoweCharleston$6K
- Thomas WeshefskyMyrtle Beach$77K
- Patrick VollmerColumbia$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.